SCYNEXIS, Inc.
SCYX
SCYX: SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
moreShow SCYX Financials
Recent trades of SCYX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SCYX's directors and management
Government lobbying spending instances
-
$20,000 Jul 20, 2010 Issue: Defense Health Issues
-
$20,000 Apr 19, 2010 Issue: Defense Health Issues
-
$20,000 Jan 20, 2010 Issue: Defense Health Issues
-
$20,000 Oct 15, 2009 Issue: Defense Health Issues
-
$20,000 Jul 20, 2009 Issue: Defense Health Issues
New patents grants
-
Patent Title: Antifungal agents with enhanced activity in acidic ph Dec. 27, 2022
-
Patent Title: Antifungal agents used in combination Sep. 07, 2021
-
Patent Title: Salts and polymorphs of scy-078 Feb. 23, 2021
-
Patent Title: Salts and polymorphs of scy-078 Aug. 06, 2019
-
Patent Title: Salts and polymorphs of scy-078 Jan. 08, 2019
-
Patent Title: Macrocyclic peptides Jul. 28, 2015
-
Patent Title: Processes for isolation and purification of enfumafungin Mar. 18, 2014
-
Patent Title: Methods for the treatment and prevention of ocular disorders Oct. 08, 2013
-
Patent Title: Macrocycles Sep. 17, 2013
-
Patent Title: Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection Dec. 11, 2012
-
Patent Title: Method for the treatment and prevention of ocular disorders May. 29, 2012
-
Patent Title: Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection Jul. 13, 2010
-
Patent Title: 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection May. 18, 2010
Federal grants, loans, and purchases
Followers on SCYX's company Twitter account
Number of mentions of SCYX in WallStreetBets Daily Discussion
Recent insights relating to SCYX
Recent picks made for SCYX stock on CNBC
ETFs with the largest estimated holdings in SCYX
Flights by private jets registered to SCYX